Takeda Announces Planned Retirement of President of Research & Development Andy Plump

September 10, 2026

OSAKA, Japan and CAMBRIDGE, Massachusetts, September 10, 2026 – Takeda (TSE:4502/NYSE:TAK) has announced that Andy Plump, M.D., Ph.D., President Research & Development (and member of the Board of Directors), will retire from Takeda, effective June 2027. Dr. Plump will remain an active member of the Takeda Executive Team and will continue to lead R&D until a successor has been announced. He will remain a member of the company’s Board of Directors through the Ordinary General Meeting of Shareholders in June 2027. Once a new President of R&D has been named, Andy will work closely with his successor to ensure a smooth and seamless transition of responsibilities to ensure continued progress and maintain momentum toward global regulatory submissions and approvals.

Takeda Representative Director, President & CEO Julie Kim commented: “Andy has led Takeda’s R&D through a significant period of transformation and growth. Under his leadership, Takeda’s pipeline was rebuilt with an innovative therapeutic area focus and we now have a robust late-stage pipeline which has delivered three transformative medicines that we are poised to launch in the coming months. On behalf of Takeda’s Board of Directors, our leadership team and colleagues around the world, we thank Andy for his unwavering dedication and visionary leadership. His contributions have advanced groundbreaking science, strengthened our R&D organization and developed exceptional talent, creating a lasting foundation to serve patients for years to come.” After Dr. Plump joined Takeda, he orchestrated a multi-year strategic and cultural transformation of R&D that resulted in a renewed focus on innovation, a streamlined global footprint and prioritized therapeutic areas of focus and created a network of partnerships and a diverse portfolio of newly approved and promising experimental therapies.

Dr. Plump has played a pivotal role in Takeda’s transformation into a global biopharmaceutical company since 2015. Under his leadership, Takeda has strengthened its leadership in orexin biology with the U.S. FDA approval of ORZEYFUL™ for narcolepsy type 1, while also receiving approval of MIMRYLO™ for erythrocytosis in adults with polycythemia vera. The organization has also developed numerous Phase 3 assets including zasocitinib, a highly selective TYK2 inhibitor poised to become a leading oral psoriasis treatment.

This leadership transition comes as Takeda executes its two-horizon growth strategy, a roadmap designed to move the company from transformation to growth acceleration. Horizon One strengthens Takeda’s competitiveness and builds a growth engine by launching three new medicines, advancing the late-stage pipeline, ensuring the resilience of core in-line brands and unlocking new capabilities and efficiencies. Horizon Two builds on Horizon One’s foundation by scaling the first wave of launches, introducing the next wave of products from the late-stage pipeline, improving speed and efficiency through advanced technology and accelerating long-term profitable growth and patient impact.

Dr. Plump commented: “It has been the privilege of a lifetime to lead Takeda’s R&D organization and work alongside colleagues so deeply committed to patients. I am proud of the progress we have made together and confident in Takeda’s scientific foundation, talented teams and continued ability to deliver life-changing medicines.”

###

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Contacts

Investor Relations

Christopher O’Reilly
[email protected]

Media Relations

Kristi Bond (Boston)
[email protected]

Tsuyoshi Tada (Tokyo)
[email protected]

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question-and-answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects”, “forecasts”, “outlook” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

**OSAKA, Japan and CAMBRIDGE, Massachusetts, September 10, 2026** – Takeda ([TSE:4502/NYSE:TAK](/investors/stock-information/)) has announced that Andy Plump, M.D., Ph.D., President Research & Development (and member of the Board of Directors), will retire from Takeda, effective June 2027. Dr. Plump will remain an active member of the Takeda Executive Team and will continue to lead R&D until a successor has been announced. He will remain a member of the company’s Board of Directors through the Ordinary General Meeting of Shareholders in June 2027. Once a new President of R&D has been named, Andy will work closely with his successor to ensure a smooth and seamless transition of responsibilities to ensure continued progress and maintain momentum toward global regulatory submissions and approvals. Takeda Representative Director, President & CEO Julie Kim commented: “Andy has led Takeda’s R&D through a significant period of transformation and growth. Under his leadership, Takeda’s pipeline was rebuilt with an innovative therapeutic area focus and we now have a robust late-stage pipeline which has delivered three transformative medicines that we are poised to launch in the coming months. On behalf of Takeda’s Board of Directors, our leadership team and colleagues around the world, we thank Andy for his unwavering dedication and visionary leadership. His contributions have advanced groundbreaking science, strengthened our R&D organization and developed exceptional talent, creating a lasting foundation to serve patients for years to come.” After Dr. Plump joined Takeda, he orchestrated a multi-year strategic and cultural transformation of R&D that resulted in a renewed focus on innovation, a streamlined global footprint and prioritized therapeutic areas of focus and created a network of partnerships and a diverse portfolio of newly approved and promising experimental therapies. Dr. Plump has played a pivotal role in Takeda’s transformation into a global biopharmaceutical company since 2015. Under his leadership, Takeda has strengthened its leadership in orexin biology with the U.S. FDA approval of ORZEYFUL™ for narcolepsy type 1, while also receiving approval of MIMRYLO™ for erythrocytosis in adults with polycythemia vera. The organization has also developed numerous Phase 3 assets including zasocitinib, a highly selective TYK2 inhibitor poised to become a leading oral psoriasis treatment. This leadership transition comes as Takeda executes its two-horizon growth strategy, a roadmap designed to move the company from transformation to growth acceleration. Horizon One strengthens Takeda’s competitiveness and builds a growth engine by launching three new medicines, advancing the late-stage pipeline, ensuring the resilience of core in-line brands and unlocking new capabilities and efficiencies. Horizon Two builds on Horizon One’s foundation by scaling the first wave of launches, introducing the next wave of products from the late-stage pipeline, improving speed and efficiency through advanced technology and accelerating long-term profitable growth and patient impact. Dr. Plump commented: “It has been the privilege of a lifetime to lead Takeda’s R&D organization and work alongside colleagues so deeply committed to patients. I am proud of the progress we have made together and confident in Takeda’s scientific foundation, talented teams and continued ability to deliver life-changing medicines.” <div style="text-align:center">\#\#\#</div> ## About Takeda Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit [www.takeda.com](/). ## Contacts ### Investor Relations **Christopher O’Reilly**<br> [[email protected]](mailto:[email protected] ) ### Media Relations **Kristi Bond (Boston)**<br> [[email protected]](mailto:[email protected]) **Tsuyoshi Tada (Tokyo)**<br> [[email protected]](mailto:[email protected]) ## Important Notice For the purposes of this notice, “press release” means this document, any oral presentation, any question-and-answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies. ## Forward-Looking Statements This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects”, “forecasts”, “outlook” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: [https://www.takeda.com/investors/sec-filings-and-security-reports/](/investors/sec-filings-and-security-reports/) or at [www.sec.gov](https://www.sec.gov). Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Takeda Announces Planned Retirement of President of Research & Development Andy Plump | Takeda Pharmaceuticals